[實施發明之形態] [0009] 本案發明人等針對輔酶Q10的活用戮力進行研究。其中，係探討活用於大腦相關疾病或血管相關疾病的預防或治療。於此，阿茲海默症的發病原因仍未必明確，惟粒線體的活性降低亦研判為其原因之一而著眼於此。 [0010] 被稱為「生物體的能量貨幣」之腺苷三磷酸(ATP)的生物合成係與醣解途徑、檸檬酸循環、電子傳遞鏈此3種系統有關。粒線體則與檸檬酸循環、及電子傳遞鏈息息相關。因此，對於生命的維持、活動而言，粒線體的活性極為重要。可舉出作為使粒線體的活性降低的原因者為還原型輔酶Q10的減少。 [0011] 粒線體常因活性含氧物而常時暴露於氧化壓力下，但可藉由抗氧化物質予以保護而免於氧化壓力。另一方面，還原型輔酶Q10不僅是電子傳遞鏈的構成成分，亦為抗氧化物質。因此，一般認為還原型輔酶Q10一減少，抗氧化活性便會降低而使粒線體發生機能異常，同時電子傳遞鏈的效率降低而使得ATP的生物合成活性降低。 [0012] 已有人指出，罹患失智症的犬隻，其腦內的輔酶Q10會減少，導致與其相關的粒線體活性降低。又，專利文獻1中記載，根據使用小鼠的實驗，輔酶Q10係有效作為健忘症的預防/治療劑。此等記載等係間接指出粒線體活性的降低或腦內輔酶Q10的減少與阿茲海默症等腦疾病的關聯，可望藉由輔酶Q10產生對阿茲海默症等腦疾病的預防/治療效果。 [0013] 然而，其雖間接指出在動物實驗中的有效性(茲參照專利文獻1)，但另外有研究報導指出，在人類臨床研究中氧化型輔酶Q10對帕金森氏症未顯示出特別的改善效果(Parkinson study group QE3 investigators, 2014)；從而輔酶Q10對大腦疾病之效果仍未必明確，其有效性亦非單獨使用輔酶Q10即可顯現。 如此，現況在於仍需要一種可預防/治療大腦相關疾病或血管相關疾病等的組成物。 [0014] 本案發明人等發現，在多種原料物質中，使其含有輔酶Q10與源自蚯蚓之原料，係有助於大腦相關疾病的改善、或血管相關疾病的改善，尤為萎縮之海馬體的恢復，並驗證特別是作為海馬體之萎縮的預防劑或治療劑的有效性，遂完成本發明。 [0015] 以下，作為本案發明之一實施形態，茲就含有輔酶Q10(coenzyme Q10)與源自蚯蚓之原料的組成物加以說明。 [0016] 輔酶Q10可使用還原型輔酶Q10(泛醇)與氧化型輔酶Q10(泛醌)任一種，惟較佳為還原型輔酶Q10。此2種輔酶Q10會隨著氧化還原反應而相互變化。還原型輔酶Q10係於生物體內經生物合成者，且具活性。還原型輔酶Q10則是近年來漸於工業上製造，可由口服攝取。另一方面，氧化型輔酶Q10係藉由食品或者工業上製造的營養補充品或醫藥品，主要以經口方式攝取至生物體內。攝取之氧化型輔酶Q10經腸道吸收後，轉換成還原型輔酶Q10而經活用。因此，本發明之組成物所含有的輔酶Q10較佳為還原型輔酶Q10，惟亦可為氧化型輔酶Q10。 [0017] 輔酶Q10可為原料粉末或加工品。加工品有粉末形態或液態製品，但不限定於此等。本實施形態中所使用的輔酶Q10較佳為粉末形態。 [0018] 1日容量之組成物所含之輔酶Q10(尤為還原型輔酶Q10)的含量需取治療上有效的量，以輔酶Q10(尤為還原型輔酶Q10)本身的量(100%)計，可取50mg～800mg，較佳取80mg～500mg，更佳為100mg～300mg。進一步而言，組成物所含之輔酶Q10的含量較佳取200mg～300mg，而為了易於調節服用量，更佳取100mg～200mg；如針對症狀較嚴重的患者，則較佳取300mg～500mg。所稱治療上有效之輔酶Q10(尤為還原型輔酶Q10)的量，係指為了盡可能抑制粒線體機能異常或恢復機能所需的1日用量。 [0019] 源自蚯蚓之原料可採用蚯蚓乾燥粉末、蚯蚓之萃取精華、或蚯蚓之抽提物等由蚯蚓取得的原料。蚯蚓乾燥粉末(包含蚯蚓冷凍乾燥粉末)可為原末或加工品。加工品有萃取粉末或抽提粉末，但不限定於此等。 [0020] 蚯蚓冷凍乾燥粉末係以蚯蚓(尤為歐美原產的紅蚯蚓)為原料使其經過冷凍乾燥而得的粉末。蚯蚓冷凍乾燥粉末係具有：將血液中的血纖維蛋白溶酶原轉換成血纖維蛋白溶解酶而顯現高纖維蛋白分解活性之作用、及直接溶解參與血液凝固的血纖維蛋白之作用。因此，蚯蚓冷凍乾燥粉末已知對血管相關疾病之大腦梗塞、缺血性腦血管障礙、糖尿病、高血壓的治療、或血栓症的預防、血纖維蛋白元酶的增加、及血小板凝聚率的增加之抑制係屬有效。此外，蚯蚓冷凍乾燥粉末係含有萃取自食用紅蚯蚓的蛋白質分解酵素，具有血纖維蛋白的溶解活性極強之特性。 [0021] 此蚯蚓冷凍乾燥粉末可使用申請人所販售之LR末I(LR末1)、LR末II(LR末2)、LR末III(LR末3)、或者其他公司製品，惟較佳為LR末III(LR末3)。 [0022] 組成物所含之源自蚯蚓之原料(尤為蚯蚓冷凍乾燥粉末)的含量需取治療上有效的量，可取10mg～200mg，較佳取10mg～100mg，更佳為20mg～80mg。進一步而言，組成物所含之源自蚯蚓之原料(尤為蚯蚓冷凍乾燥粉末)的含量較佳取60mg～100mg，而為了易於調節服用量，更佳取10mg～50mg；如針對症狀較嚴重的患者，則較佳取100mg～200mg。此外，治療上有效之源自蚯蚓之原料(尤為蚯蚓冷凍乾燥粉末)的量係指為了溶解一部分的血栓所需的1日用量。 [0023] 組成物所含之源自蚯蚓之原料(尤為蚯蚓冷凍乾燥粉末)的比例可取0.1倍～1.5倍，較佳取0.3倍～1倍(等量)，更佳取0.4倍～0.7倍，宜為0.5倍左右。換言之，組成物所含之源自蚯蚓之原料(尤為蚯蚓冷凍乾燥粉末)的比例，相對於輔酶Q10的量可取0.1倍～4倍，較佳取0.2倍～3倍，更佳取0.4倍～2倍。 [0024] 組成物之形態，可選自軟膠囊、硬膠囊、打錠、粉末、顆粒、飲劑等。較佳為軟膠囊或粉末、顆粒之形態，更佳為軟膠囊之形態。例如，可將粉末形態之組成物混於經管營養劑等，而使組成物含於經管營養劑。藉此，對於不方便口服攝取的患者，亦可投予組成物。 [0025] 組成物中，除輔酶Q10與源自蚯蚓之原料外，亦可含有維生素、礦物質、碳水化合物、脂質等營養素、及/或抗氧化物質、及/或營養補充品素材等有用於維持、改善健康的素材。 [0026] 組成物並非採用特別限定之使用形態，可採用食品、營養補充品、或醫藥品等適宜之使用形態。例如，組成物可作成根據醫師建議的營養補充品之形態。 [0027] 組成物對大腦相關疾病(尤為稱作海馬體的萎縮之疾病)的預防或治療係屬有效，係發揮作為此類疾病用之醫藥組成物、治療藥、預防藥、或治療/預防用組成物的機能。治療標的之大腦相關疾病係包含阿茲海默症、失智症、帕金森氏症、肌痛性腦脊髓炎、及多系統萎縮症等，但不限定於此等。又，組成物對血管相關疾病的預防或治療亦屬有效，係發揮作為此類疾病用之醫藥組成物、治療藥、預防藥、或治療/預防用組成物的機能。治療標的之血管相關疾病係包含靜脈曲張或深層靜脈栓塞，但不限定於此等。 以下，就本發明之實施例加以說明。 [實施例1] [0028] ＜硬膠囊＞ 作為本發明組成物之實施例1，係如下調製含有輔酶Q10與蚯蚓冷凍乾燥粉末的硬膠囊劑。亦即，將包含還原型輔酶Q10穩定化粉末(Kaneka股份有限公司製：還原型coenzyme Q10 P30)與蚯蚓冷凍乾燥粉末(輝龍股份有限公司製：LR末III)的各成分素材以一般的粉末混合機混合後，填入至硬膠囊而作成硬膠囊劑(製劑)。此外，還原型輔酶Q10穩定化粉末(P30)係表示為含有30%的還原型輔酶Q10的粉末，例如還原型輔酶Q10穩定化粉末若為180mg，則所含之還原型輔酶Q10為60mg。 [0029] 1顆膠囊中之各成分素材的成分量為還原型輔酶Q10穩定化粉末(P30) 180mg(其中還原型輔酶Q10為60mg)、蚯蚓冷凍乾燥粉末(LR末III) 30mg、食用酵母(鋅、銅、硒酵母) 10mg、維生素B1 10mg、維生素B2 5mg、維生素B6 5mg、維生素B12 20mg、葉酸 0.1mg、維生素D3 0.6mg、賦形劑 89.3mg。 [實施例2] [0030] ＜散劑＞ 作為本發明組成物之實施例2，係如下調製含有輔酶Q10與蚯蚓冷凍乾燥粉末的散劑。亦即，將包含還原型輔酶Q10穩定化粉末(P30)與蚯蚓冷凍乾燥粉末(LR末III)的各成分素材以一般的粉末混合機混合後，作成散劑(製劑)。 [0031] 1袋中之各成分素材的成分量為還原型輔酶Q10穩定化粉末(P30) 360mg(其中還原型輔酶Q10為120mg)、蚯蚓冷凍乾燥粉末(LR末III) 60mg、食用酵母(鋅、銅、硒酵母) 20mg、維生素B1 20mg、維生素B2 10mg、維生素B6 10mg、維生素B12 40mg、葉酸 0.2mg、維生素D3 1.2mg、賦形劑 120.6mg。 [實施例3] [0032] ＜軟膠囊＞ 作為本發明組成物之實施例3，係如下調製含有輔酶Q10與蚯蚓冷凍乾燥粉末的軟膠囊劑。亦即，將包含還原型輔酶Q10穩定化粉末(P30)與蚯蚓冷凍乾燥粉末(LR末III)的各成分素材以一般的粉末混合機混合後，填充於膠囊而作成軟膠囊劑(製劑)。 [0033] 1顆膠囊中之各成分素材的成分量為還原型輔酶Q10穩定化粉末(P30) 50mg(其中還原型輔酶Q10約為16.67mg)、MIHARA RUBELLUS粉末(MIHARA RUBELLUS製) 30mg、維生素E 10mg、菜籽油 139.7mg、Poem DO-100V(理研維生素公司製) 70mg、大豆卵磷脂 0.3mg。此外，MIHARA RUBELLUS粉末為MIHARA RUBELLUS製蚯蚓乾燥粉末。 [0034] ＜疾病的改善效果＞ 藉由攝取實施例1～3之組成物(硬膠囊劑、散劑、軟膠囊劑)之任一者，可看出包含失智症之阿茲海默症等腦疾病患者之症狀的改善、靜脈曲張患者之症狀的改善、深層靜脈曲張患者之症狀的改善。就其具體的改善案例，顯示出對阿茲海默症之海馬體的萎縮的改善案例。 [0035] 對經診斷為阿茲海默症的2名患者，以1天4顆膠囊投予＜實施例1＞中所調製的製劑達3個月。臨床效果的確認，係透過使用大腦影像分析軟體VBM Tutorial(SPM8)分析投予前後所拍攝之大腦的MRI影像來進行。 [0036] 圖1為其中1名患者之患者A(經診斷為伴有中度海馬體分解之重度阿茲海默症的82歲男性)於投予前之大腦海馬體附近之水平剖面的MRI影像。圖2為該患者A於投予後之大腦海馬體附近之水平剖面的MRI影像。由此MRI影像可確認，與投予前相比，於投予後海馬體增大。 [0037] 使用SPM8分析的結果，投予後之2名患者大腦海馬體的容積，與投予前相比，確認增大12%～9%。由此顯示，實施例1中所調製的製劑(硬膠囊劑)，對於改善阿茲海默症患者大腦海馬體的萎縮係屬有效。 [0038] 此外，本案發明非限於本實施形態，可採用其他各種實施形態。 [產業上可利用性] [0039] 本案發明可利用於醫藥品、營養補充品、或食品等領域。[Formation of the Invention] [0009] The inventors of the present invention conducted research on the use of coenzyme Q10. Among them, it is to explore the prevention or treatment of brain-related diseases or vascular-related diseases. Here, the cause of Alzheimer's disease is still not clear, but the decrease in the activity of the mitochondria is also considered as one of the reasons for this. [0010] The biosynthesis system of adenosine triphosphate (ATP), which is called "energy energy of a living body", is related to the three systems of the glycolytic pathway, the citric acid cycle, and the electron transport chain. The mitochondria are closely related to the citric acid cycle and the electron transport chain. Therefore, the activity of the mitochondria is extremely important for the maintenance and activity of life. The decrease in the activity of the mitochondria is a decrease in the reduced coenzyme Q10. [0011] The mitochondria are often exposed to oxidative stress due to active oxygenates, but can be protected from oxidative stress by oxidation resistant materials. On the other hand, the reduced coenzyme Q10 is not only a constituent component of the electron transport chain but also an antioxidant. Therefore, it is generally believed that as the reduced coenzyme Q10 is reduced, the antioxidant activity is lowered to cause abnormal function of the mitochondria, and the efficiency of the electron transport chain is lowered to lower the biosynthesis activity of ATP. [0012] It has been pointed out that in dogs suffering from dementia, the coenzyme Q10 in the brain is reduced, resulting in a decrease in the mitochondrial activity associated therewith. Further, Patent Document 1 discloses that Coenzyme Q10 is effective as a preventive/therapeutic agent for amnesia according to an experiment using a mouse. These records indirectly indicate that the decrease in mitochondrial activity or the decrease in coenzyme Q10 in the brain is associated with brain diseases such as Alzheimer's disease, and it is expected that the prevention of brain diseases such as Alzheimer's disease by coenzyme Q10 is expected. /treatment effect. [0013] However, although it indirectly indicates the effectiveness in animal experiments (refer to Patent Document 1), another research report indicates that oxidized coenzyme Q10 does not show a particular effect on Parkinson's disease in human clinical studies. Improvement effect (Parkinson study group QE3 investigators, 2014); thus the effect of coenzyme Q10 on brain diseases is still not clear, and its effectiveness can not be manifested by using coenzyme Q10 alone. Thus, the current situation is that there is still a need for a composition that can prevent/treat brain-related diseases or blood vessel-related diseases and the like. [0014] The inventors of the present invention have found that a variety of raw material substances, including coenzyme Q10 and a raw material derived from sputum, contribute to improvement of brain-related diseases, or improvement of vascular-related diseases, particularly atrophied hippocampus. The present invention has been completed and verified to be effective as a prophylactic or therapeutic agent for atrophy of the hippocampus. [0015] Hereinafter, as an embodiment of the present invention, a composition containing coenzyme Q10 (coenzyme Q10) and a raw material derived from ruthenium will be described. [0016] Coenzyme Q10 may be any of reduced coenzyme Q10 (panthenol) and oxidized coenzyme Q10 (ubiquinone), but is preferably reduced coenzyme Q10. The two coenzymes Q10 change with each other with the redox reaction. The reduced coenzyme Q10 is biosynthesized in vivo and is active. Reduced coenzyme Q10 has been industrially produced in recent years and can be taken orally. On the other hand, the oxidized coenzyme Q10 is mainly ingested into a living body by a food supplement or a pharmaceutical supplement or a pharmaceutical product. The ingested oxidized coenzyme Q10 is absorbed into the intestinal tract and converted into reduced coenzyme Q10 for use. Therefore, the coenzyme Q10 contained in the composition of the present invention is preferably reduced coenzyme Q10, but may also be oxidized coenzyme Q10. [0017] Coenzyme Q10 may be a raw material powder or a processed product. The processed product has a powder form or a liquid product, but is not limited thereto. The coenzyme Q10 used in the present embodiment is preferably in a powder form. [0018] The content of the coenzyme Q10 (especially the reduced coenzyme Q10) contained in the composition of the 1-day capacity is required to be therapeutically effective, and is based on the amount (100%) of the coenzyme Q10 (especially the reduced coenzyme Q10) itself. It is preferably 50 mg to 800 mg, preferably 80 mg to 500 mg, more preferably 100 mg to 300 mg. Further, the content of the coenzyme Q10 contained in the composition is preferably from 200 mg to 300 mg, and more preferably from 100 mg to 200 mg for easy adjustment of the dosage, and preferably from 300 mg to 500 mg for patients with severe symptoms. The amount of the therapeutically effective coenzyme Q10 (especially reduced coenzyme Q10) refers to the amount of one day required to suppress granule function abnormality or restore function as much as possible. [0019] The raw material derived from bismuth may be a raw material obtained from hydrazine, such as a dry powder, an extract of hydrazine, or an extract of hydrazine. The dry powder (including the lyophilized powder) may be a raw or processed product. The processed product has an extraction powder or an extracted powder, but is not limited thereto. [0020] The lyophilized powder is a powder obtained by freeze-drying ruthenium (especially red sorghum originally produced in Europe and America). The lyophilized powder has a function of converting plasminogen in blood into fibrinolytic enzyme to exhibit high fibrinolytic activity, and directly dissolving fibrin which is involved in blood coagulation. Therefore, lyophilized powder is known to treat cerebral infarction, ischemic cerebrovascular disease, diabetes, hypertension, or prevention of thrombosis, increase in fibrinogenase, and increase in platelet aggregation rate for vascular-related diseases. The inhibition system is effective. Further, the lyophilized powder contains a proteolytic enzyme extracted from edible red peony, and has a highly soluble activity of fibrin. [0021] The lyophilized powder can be used as LR end I (LR end 1), LR end II (LR end 2), LR end III (LR end 3), or other company products sold by the applicant, but Jia is LR end III (LR end 3). The content of the raw material derived from strontium (especially lyophilized powder) contained in the composition is required to be therapeutically effective, and may be 10 mg to 200 mg, preferably 10 mg to 100 mg, more preferably 20 mg to 80 mg. Further, the content of the raw material derived from strontium (especially lyophilized powder) contained in the composition is preferably from 60 mg to 100 mg, and more preferably from 10 mg to 50 mg for easy adjustment of the dosage; For patients, it is preferred to take 100 mg to 200 mg. In addition, the amount of a therapeutically effective sputum-derived material (especially lyophilized powder) refers to the amount of one day required to dissolve a portion of the thrombus. [0023] The ratio of the raw material derived from cerium (especially lyophilized powder) contained in the composition may be 0.1 to 1.5 times, preferably 0.3 to 1 times (equal amount), more preferably 0.4 to 0.7 times. It should be about 0.5 times. In other words, the ratio of the raw material derived from ruthenium (especially lyophilized powder) contained in the composition may be 0.1 to 4 times, preferably 0.2 to 3 times, more preferably 0.4 times the amount of the coenzyme Q10. 2 times. [0024] The form of the composition may be selected from the group consisting of a soft capsule, a hard capsule, a tablet, a powder, a granule, a drink, and the like. It is preferably in the form of a soft capsule or a powder or a granule, more preferably in the form of a soft capsule. For example, a composition in a powder form may be mixed with a nutrient or the like, and the composition may be contained in a via nutrient. Thereby, a composition can be administered to a patient who is inconvenient to take it orally. [0025] In the composition, in addition to coenzyme Q10 and raw materials derived from bismuth, vitamins, minerals, carbohydrates, lipids and other nutrients, and / or antioxidant substances, and / or nutritional supplement materials may also be used. Maintain and improve healthy materials. The composition is not particularly limited in its use form, and may be in a suitable use form such as a food, a nutritional supplement, or a pharmaceutical. For example, the composition can be in the form of a nutritional supplement as suggested by the physician. [0027] The composition is effective for the prevention or treatment of a brain-related disease (especially a disease of atrophy of the hippocampus), and is a pharmaceutical composition, a therapeutic drug, a preventive drug, or a treatment/prevention for such a disease. Use the function of the composition. The brain-related diseases of the treatment target include, but are not limited to, Alzheimer's disease, dementia, Parkinson's disease, myalgic encephalomyelitis, and multiple system atrophy. Further, the composition is also effective for the prevention or treatment of a blood vessel-related disease, and functions as a pharmaceutical composition, a therapeutic drug, a preventive drug, or a therapeutic/preventive composition for such a disease. The vascular-related disease of the treatment target includes varicose veins or deep vein thrombosis, but is not limited thereto. Hereinafter, embodiments of the invention will be described. [Example 1] <Hard Capsule> As Example 1 of the composition of the present invention, a hard capsule containing Coenzyme Q10 and a lyophilized powder was prepared as follows. In other words, each component material containing a reduced coenzyme Q10 stabilized powder (manufactured by Kaneka Co., Ltd.: reduced type coenzyme Q10 P30) and a lyophilized powder (manufactured by Huilong Co., Ltd.: LR) is used as a general powder. After mixing with a mixer, it was filled into hard capsules to prepare a hard capsule (formulation). Further, the reduced coenzyme Q10 stabilized powder (P30) is a powder containing 30% of reduced coenzyme Q10. For example, if the reduced coenzyme Q10 stabilized powder is 180 mg, the reduced coenzyme Q10 is 60 mg. [0029] The component amount of each component material in one capsule is 180 mg of reduced coenzyme Q10 stabilized powder (P30) (60 mg of reduced coenzyme Q10), 30 mg of lyophilized powder (LR end III), and edible yeast ( Zinc, copper, selenium yeast 10mg, vitamin B1 10mg, vitamin B2 5mg, vitamin B6 5mg, vitamin B12 20mg, folic acid 0.1mg, vitamin D3 0.6mg, excipient 89.3mg. [Example 2] <Powder> As Example 2 of the composition of the present invention, a powder containing Coenzyme Q10 and hydrazine freeze-dried powder was prepared as follows. In other words, each component material containing the reduced coenzyme Q10 stabilized powder (P30) and the mash freeze-dried powder (LR end III) is mixed in a general powder mixer to prepare a powder (formulation). [0031] The component amount of each component material in one bag is reduced coenzyme Q10 stabilized powder (P30) 360 mg (including reduced coenzyme Q10 is 120 mg), lyophilized powder (LR end III) 60 mg, edible yeast (zinc) , copper, selenium yeast) 20mg, vitamin B1 20mg, vitamin B2 10mg, vitamin B6 10mg, vitamin B12 40mg, folic acid 0.2mg, vitamin D3 1.2mg, excipient 120.6mg. [Example 3] <Soft capsule> As Example 3 of the composition of the present invention, a soft capsule containing Coenzyme Q10 and lyophilized powder was prepared as follows. In other words, each component material containing the reduced coenzyme Q10 stabilized powder (P30) and the lyophilized powder (LR end III) is mixed in a general powder mixer, and then filled in a capsule to prepare a soft capsule (formulation). [0033] The component amount of each component material in one capsule is reduced coenzyme Q10 stabilized powder (P30) 50 mg (including reduced coenzyme Q10 is about 16.67 mg), MIHARA RUBELLUS powder (manufactured by MIHARA RUBELLUS) 30 mg, vitamin E 10 mg, rapeseed oil 139.7 mg, Poem DO-100V (manufactured by Riken Vitamin Co., Ltd.) 70 mg, and soybean lecithin 0.3 mg. Further, the MIHARA RUBELLUS powder is a dry powder of MIHARA RUBELLUS. <Improvement Effect of Disease> By ingesting any of the compositions (hard capsules, powders, soft capsules) of Examples 1 to 3, it can be seen that Alzheimer's disease including dementia Improvement in symptoms of patients with brain disease, improvement in symptoms of patients with varicose veins, and improvement in symptoms of patients with deep varices. As for its specific improvement case, it shows an improvement case of the atrophy of the hippocampus of Alzheimer's disease. [0035] For 2 patients diagnosed with Alzheimer's disease, the preparation prepared in <Example 1> was administered in 4 capsules per day for 3 months. Confirmation of clinical effects was performed by analyzing the MRI images of the brains taken before and after the administration using the brain image analysis software VBM Tutorial (SPM8). 1 is an MRI of a horizontal section of a patient's A (an 82-year-old male diagnosed with severe Alzheimer's disease with moderate hippocampal breakdown) in the vicinity of the hippocampus before administration. [0036] FIG. image. Figure 2 is an MRI image of a horizontal section of the patient's A near the hippocampus of the brain after administration. From this MRI image, it was confirmed that the hippocampus was increased after administration as compared with before administration. [0037] Using the results of the SPM8 analysis, the volume of the hippocampus of the two patients after administration was confirmed to increase by 12% to 9% compared with that before administration. From this, it was revealed that the preparation prepared in Example 1 (hard capsule) was effective for improving the atrophy of the hippocampus of the brain of Alzheimer's disease patients. Further, the present invention is not limited to the embodiment, and various other embodiments may be employed. [Industrial Applicability] [0039] The invention of the present invention can be utilized in the fields of pharmaceuticals, nutritional supplements, or foods.